Give us a call 215-275-1556

A Cloudy Future for the Sunshine Act

The due date for posting another year’s worth of Physician Payment  Sunshine Act (a.k.a. Open Payments) data is fast approaching.  But the future for the Sunshine Act is cloudy.  A new Republican President combined with a recent academic study cast doubt on the...

Is Drug Price Transparency DOA?

Once again drug price transparency is in the news. Now it appears that efforts to improve pricing visibility are dead on arrival.  If we look at recent actions by Pfizer and Mylan, it may well be.  At the very least, their actions cast doubt Brent Saunders’...

Drug Pricing Need Not Be This Hard

Mylan’s EpiPen continues making news, prompting patients to compare drug prices. They look at the prices in Canada, our closest neighbor, and they wonder why the prices here are two to three times higher for the same product. It is both dramatic and unsettling....

Transparency’s Uncertain Future

I just returned from speaking at CBI’s 10th Annual Forum on Transparency and Aggregate Spend.  After 10 years and 3 CMS Open Payments reporting cycles, I’m struck by how uncertain the once bright future of the Sunshine Act is.  Overall, the industry...

Enforcing Sunshine

As noted in a recent article from Policy and Medicine, we have now received our first definitive indication that the OIG and CMS are moving to enforce the Sunshine Act reporting requirements.  According to Mary Riordan, senior counsel at the Health and Human...